These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 25754350)

  • 1. Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?
    Paiva B; Puig N; García-Sanz R; San Miguel JF;
    Clin Cancer Res; 2015 May; 21(9):2001-8. PubMed ID: 25754350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deep Response in Multiple Myeloma: A Critical Review.
    Fulciniti M; Munshi NC; Martinez-Lopez J
    Biomed Res Int; 2015; 2015():832049. PubMed ID: 26783530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple Myeloma Minimal Residual Disease.
    Paiva B; García-Sanz R; San Miguel JF
    Cancer Treat Res; 2016; 169():103-122. PubMed ID: 27696260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRD Assessment in Multiple Myeloma: Progress and Challenges.
    Bertamini L; D'Agostino M; Gay F
    Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How?
    Roshal M
    Semin Hematol; 2018 Jan; 55(1):4-12. PubMed ID: 29759152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
    Waldschmidt JM; Anand P; Knoechel B; Lohr JG
    Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What to do with minimal residual disease testing in myeloma.
    Manasanch EE
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical Significance and Detection Techniques of Minimal Residual Disease in Multiple Myeloma-Review].
    Yu Q; Shi JM; Tao Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):961-964. PubMed ID: 28641668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity.
    Berger N; Kim-Schulze S; Parekh S
    Adv Exp Med Biol; 2018; 1100():141-159. PubMed ID: 30411265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.
    Mathis S; Chapuis N; Borgeot J; Maynadié M; Fontenay M; Béné MC; Guy J; Bardet V
    Cytometry B Clin Cytom; 2015 Mar; 88(2):101-9. PubMed ID: 25399680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and clinical follow-up after treatment of multiple myeloma.
    Rasmussen T; Knudsen LM; Huynh TK; Johnsen HE
    Acta Haematol; 2004; 112(1-2):105-10. PubMed ID: 15179010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurable Residual Disease and Decision-Making in Multiple Myeloma.
    Derman BA; Fonseca R
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):477-495. PubMed ID: 38184470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
    Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma: disease response assessment.
    Zamagni E; Tacchetti P; Terragna C; Cavo M
    Expert Rev Hematol; 2016 Sep; 9(9):831-7. PubMed ID: 27409577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New criteria for response assessment: role of minimal residual disease in multiple myeloma.
    Paiva B; van Dongen JJ; Orfao A
    Blood; 2015 May; 125(20):3059-68. PubMed ID: 25838346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
    Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
    Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
    Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.
    Putkonen M; Kairisto V; Juvonen V; Pelliniemi TT; Rauhala A; Itälä-Remes M; Remes K
    Eur J Haematol; 2010 Nov; 85(5):416-23. PubMed ID: 20722702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
    Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
    Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
    Martinez-Lopez J; Alonso R; Wong SW; Rios R; Shah N; Ruiz-Heredia Y; Sanchez-Pina JM; Sanchez R; Bahri N; Zamanillo I; Poza M; Buenache N; Encinas C; Juarez L; Miras F; Collado L; Barrio S; Martin T; Cedena MT; Wolf J
    J Hematol Oncol; 2021 Aug; 14(1):126. PubMed ID: 34404440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.